| Identification | Back Directory | [Name]
GABOXADOL HYDROCHLORIDE | [CAS]
85118-33-8 | [Synonyms]
MK 0928)
Einecs 285-687-7
gaboxadol hydrochloride
Gaboxadol HCl (Lu 02-030
GaboxadolHydrochloride>
Lu 02-030 (hydrochloride)
Gaboxadol hydrochloride solid, >=98% (HPLC)
THIP HYDROCHLORIDE (GABOXADOL) POST-SYNA PTIC GABA RE
4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol, (HCl salt)
4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate
4,5,6,7-TETRAHYDROISOXAZOLO[5,4-C]PYRIDIN-3-OL HCL, GABOXADOL-HCL
4,5,6,7-tetrahydroisoxazolo[5,4-c]pyridin-3(2H)-one monohydrochloride
4,5,6,7-tetrahydro-[1,2]oxazolo[5,4-c]pyridin-6-ium-3-olate:hydrochloride
Isoxazolo[5,4-c]pyridin-3(2H)-one, 4,5,6,7-tetrahydro-, Monohydrochloride
THIP hydrochloride, 4,5,6,7-Tetrahydroisoxazolo[5,4-c]pyridin-3-ol hydrochloride | [EINECS(EC#)]
285-687-7 | [Molecular Formula]
C6H9ClN2O2 | [MDL Number]
MFCD00055180 | [MOL File]
85118-33-8.mol | [Molecular Weight]
176.601 |
| Chemical Properties | Back Directory | [Melting point ]
236 °C | [storage temp. ]
Keep in dark place,Inert atmosphere,Room temperature | [solubility ]
ethanol: soluble0.91mg/mL | [form ]
solid | [color ]
white | [Merck ]
14,4321 | [InChI]
1S/C6H8N2O2.ClH/c9-6-4-1-2-7-3-5(4)10-8-6;/h7H,1-3H2,(H,8,9);1H | [InChIKey]
ZDZDSZQYRBZPNN-UHFFFAOYSA-N | [SMILES]
Cl[H].Oc1noc2CNCCc12 |
| Hazard Information | Back Directory | [Uses]
As a molecular probe to study GABA receptors. | [Uses]
GABAergic Agonist | [Uses]
Gaboxadol is a sleep aid drug used for the treatment of chronic pain and insomnia. Gaboxadol is also known to exhibit antidepressant like properties through its agonistic activities towards GABA sites
. | [General Description]
Gaboxadol, also referred to as 4,5,6,7-tetrahydroisoxazolo(5,4-c)pyridin-3-ol (THIP), is a GABA site agonist. It has great affinity to the δ subunit of extrasynaptic high-affinity GABAA receptors. Gaboxadol was first developed for the treatment of schizophrenia, epilepsy, primary insomnia and Huntington′s disease. It can easily cross the blood-brain barrier and is rapidly absorbed by the body. | [Biochem/physiol Actions]
GABAA receptor agonist. | [in vivo]
Gaboxadol hydrochloride (intraperitoneal injection; 0.5, 1, 1.5, 2, 3, 4, or 5 mg/kg; once daily; three-day interval) normalizes the distance traveled by Fmr1 KO2 mice to WT activity levels at 0.5 mg/kg, additionally, this compound has no effect on locomotor activity in Fmr1 KO2 mice[2]. | Animal Model: | Fmr1?KO2 mice (deletion of the promoter and first exon of?Fmr1?resulting in mRNA and protein null mice)[2] | | Dosage: | 0.5, 1, 1.5, 2, 3, 4, or 5 mg/kg | | Administration: | Intraperitoneal injection | | Result: | Normalized Hyperactivity Observed in?Fmr1?KO2 mice. |
| [storage]
Store at RT |
|
|